Soyuan Bio signed an authorization agreement to develop DB102 new indications.

Dr. Michael F. Haller, Chief Commercial Officer, soyuan Bio, said, "The acquisition of the world's first new drug in late clinical terms by Soyuan Bio's acquisition of its unique precision medical platform not only makes a breakthrough in pre-existing indications, but also holds potential uses and significant value in other indications." by fulfilling this agreement,
, in addition to pooling resources through DB102's international clinical trials for the treatment of high-risk diffuse large B-cell lymphoma and glioma, the potential of DB102 can also be explored and expanded in a more timely and adequate manner in other diseases through cooperative means.
this cooperation not only extends the existing product pipeline of Soyuan Bio to new indications, but also enables Soyuan Bio to generate revenue before the release of the DB102 Clinical First Indications ENGINE research data, highlighting the many advantages of soyuan bio-business model."
original title: Enterprises and Soyuan Bio signed an licensing agreement with Rumpus Therapeutics to develop a new DB102 (Enzastaurin) adaptation.